Market news

Based on the average brokerage recommendation (ABR), Veeva (VEEV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Veeva Systems was downgraded to neutral after a 40%+ rally as valuation looks stretched despite strong growth and Falcon AI demand. Click for more on VEEV stock.

Veeva Systems (VEEV) closed the most recent trading day at $280.68, moving +2.12% from the previous trading session.

VEEV's AI-powered Study Builder Agent automates clinical study setup, cutting manual work while strengthening its connected Clinical Data ecosystem.

Veeva Systems (NYSE:VEEV) has outperformed the market over the past 10 years by 7.41% on an annualized basis producing an average annual return of 21.03%. Currently, Veeva Systems has a market capitalization of $44.69

In recent days, Veeva Systems has rolled out new AI-powered tools such as Veeva Study Builder Agent and Veeva Falcon Router, while announcing major customer wins including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a global deployment of Veeva Vault CRM. Together, these developments highlight Veeva’s push to embed agentic AI across clinical, safety, quality, and commercial workflows, reinforcing its role as an end-to-end software partner for life sciences...

Jensen’s Allen Bond says investors may be overlooking Veeva, Verisk and Broadridge as AI reshapes software and business services.

Veeva Systems launches new AI study design agent Veeva Systems (VEEV) has unveiled Veeva Study Builder Agent, an AI tool that configures its EDC and Data Quality System directly from a clinical study protocol, aiming to streamline and standardize trial setup. Recent AI product launches and new client wins have arrived alongside a sharp 71.27% 90 day share price return and an 8.97% 30 day share price return for Veeva Systems, while the 1 year total shareholder return is slightly down 2.59%,...

Veeva Systems (NYSE: VEEV) today announced Veeva Study Builder Agent, a new AI solution that configures Veeva EDC and Veeva DQS (Data Quality System) directly from a study protocol. By reusing an organization's existing standards and leveraging the CDISC Unified Study Definitions Model (USDM), the agent ensures faster, more deterministic study builds.

Veeva Systems (VEEV) stock rises as a top-20 biopharma picks Vault CRM, expanding its reach to 14 of the top biopharma companies. Read more here.

Veeva Systems (NYSE: VEEV) today announced a new top 20 biopharma commitment, adding to recent selections by Amgen, Biogen, Eli Lilly and Company, and Regeneron. With more than 190 live customers and global commitments from 14 of the top 20 biopharmas, Vault CRM is the next generation of CRM, delivering new agentic and core capabilities to increase field productivity and effectiveness.

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.

Detailed price information for Veeva Systems Inc (VEEV-N) from The Globe and Mail including charting and trades.

Veeva (VEEV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Detailed price information for Tvardi Therapeutics Inc (TVRD-Q) from The Globe and Mail including charting and trades.

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Veeva Systems (NYSE: VEEV) today announced that Amgen plans to deploy Veeva Vault CRM globally, building on a collaboration spanning more than a decade.

Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Michael Burry backs Veeva (VEEV) but trims after a sharp rally; he also calls Snowflake (SNOW) overvalued amid AI/quantum risks—read more.

Motley Fool Press Release.

During the August 31 episode of Mad Money, Jim Cramer examined the sharp rotation back into enterprise software following the forced unwinding of bearish hedge fund positions. Mentioning Veeva Systems Inc. (NYSE:VEEV) and Salesforce, Inc. (NYSE:CRM) as examples of sector leaders, he commented: Situational Awareness just despised enterprise software and Veeva Systems, number three, up […]

Veeva Systems (NYSE: VEEV) today announced participation in the following investor conferences:

Revenue hit $928M with 18% growth as Vault CRM adoption accelerates.

Veeva Systems Inc. (NYSE:VEEV) delivered a fiscal second-quarter report that renewed interest in profitable software growth. Revenue rose 18% year over year to $928 million, while subscription revenue increased 16% to $766.8 million. GAAP operating income climbed 40% to $275 million, lifting the operating margin to 29.6% from 24.8%. That improvement was real, but the […]

Veeva Systems Inc. delivered accelerating revenue growth of 18% in Q2/27, surpassing guidance and analyst expectations. Click for this VEEV stock update.

Detailed price information for Veeva Systems Inc (VEEV-N) from The Globe and Mail including charting and trades.

Detailed price information for Veeva Systems Inc (VEEV-N) from The Globe and Mail including charting and trades.

Detailed price information for Veeva Systems Inc (VEEV-N) from The Globe and Mail including charting and trades.

Veeva Systems' recent beat-and-raise quarter has investors feeling bullish.

Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) jumped 17% in the afternoon session after the company reported second-quarter financial results that exceeded Wall Street expectations for revenue and adjusted earnings.

What the latest earnings and guidance tell you about Veeva Systems Veeva Systems (VEEV) just reported quarterly results that came in ahead of analyst expectations and paired them with higher guidance, putting fresh attention on how its AI focused life sciences cloud products are performing. The company reported second quarter revenue of US$927.96 million compared with US$789.08 million a year earlier. Net income was US$273.43 million compared with US$200.31 million a year ago, with diluted...

Veeva Systems (VEEV) surged 15% after earnings and revenue beat estimates and management raised FY2027 guidance.

The cloud specialist in the life sciences industry delivered remarkably solid results.